Last reviewed · How we verify
Dronedarone Hydrochloride Tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dronedarone Hydrochloride Tablets (Dronedarone Hydrochloride Tablets) — Shandong New Time Pharmaceutical Co., LTD. Dronedarone blocks multiple cardiac ion channels including potassium, sodium, and calcium channels, and has antiadrenergic properties.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dronedarone Hydrochloride Tablets TARGET | Dronedarone Hydrochloride Tablets | Shandong New Time Pharmaceutical Co., LTD | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dronedarone Hydrochloride Tablets CI watch — RSS
- Dronedarone Hydrochloride Tablets CI watch — Atom
- Dronedarone Hydrochloride Tablets CI watch — JSON
- Dronedarone Hydrochloride Tablets alone — RSS
Cite this brief
Drug Landscape (2026). Dronedarone Hydrochloride Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/dronedarone-hydrochloride-tablets. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing